Results 71 to 80 of about 657,649 (153)

Resistance to TRK inhibition mediated by convergent MAPK pathway activation

, 2019
TRK fusions are found in a variety of cancer types, lead to oncogenic addiction, and strongly predict tumor-agnostic efficacy of TRK inhibition(1-8). With the recent approval of the first selective TRK inhibitor, larotrectinib, for patients with any TRK ...
Toska, Eneda, Mattar, Marissa, Scaltriti, Maurizio, Marissa Mattar, Lanman, Richard B., Sophie Shifman, Selcuklu, S. Duygu, Tuch, Brian B., Kulick, Amanda, David M. Hyman, Brian Houck-Loomis, Ebata, Kevin, Houck-Loomis, Brian, Samoila, Aliaksandra, de Stanchina, Elisa, Hyman, David M., Somwar, Romel, Shifman, Sophie, Sean Guzman, Nagy, Rebecca J., Rebecca J. Nagy, Emiliano Cocco, Helen H. Won, Yaeger, Rona, S. Duygu Selçuklu, Eneda Toska, Hechtman, Jaclyn F., Michael F. Berger, Jaclyn F. Hechtman, Richard B. Lanman, Juber A. Patel, Marc Ladanyi, Sandra Misale, Rona Yaeger, Aliaksandra Samoila, Schram, Alison M., Amanda Kulick, Romel Somwar, Kevin Ebata, Alexander Drilon, Brian B. Tuch, Alison M. Schram, Cownie, James, Berger, Michael F., Drilon, Alexander, Misale, Sandra, Ryan Ptashkin, James Cownie, Razavi, Pedram, Ladanyi, Marc, Maurizio Scaltriti, Won, Helen H., Cocco, Emiliano, Ptashkin, Ryan, Guzman, Sean, Patel, Juber A., Pedram Razavi, Elisa de Stanchina   +57 more
core   +1 more source

Clinical Outcomes, Treatment Patterns, and Molecular Heterogeneity of TFE3‐Rearranged Renal Cell Carcinoma: A Multicenter Real‐World Study

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Background TFE3‐rearranged renal cell carcinoma (TFE3‐rRCC) is uncommon and encompasses biologically diverse tumors, while evidence to guide systemic treatment remains sparse. We examined clinical outcomes, treatment patterns, and molecular features in a multicenter real‐world cohort.
Shuxuan Zhu, Siqi Zhou, Xi Tian, Jun Wang, Ze Wang, Jun Jiang, Qiuli Liu, Xin Gou, Xiang Zhou, Jun Gu, Jianfeng Yang, Jianhui Chen, Shushang Chen, Wenfeng Wang, Aihetaimujiang Anwaier, Kun Chang, Yuanyuan Qu, James Brugarolas, Wenhao Xu, Hailiang Zhang, Dingwei Ye   +20 more
wiley   +1 more source

Schwann Cells in Physical Nerve Injury and Tumor Perineural Invasion: A Functional Overview and Comparison

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT The nervous system exhibits remarkable stability, making its repair challenging. Compared to the central nervous system, peripheral nerve injuries demonstrate a greater potential for regeneration. Schwann cells, the unique myelinating glial cells of the peripheral nervous system, possess striking plasticity and support nerve regeneration ...
Yanni Zheng, Xin Chen, Jiachen Liu, Jiayi Chen, Lei Tang, Wenjun Liu, Yuxin Lin, Xuedong Wei   +7 more
wiley   +1 more source

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors

, 2017
Larotrectinib, a selective TRK tyrosine kinase inhibitor (TKI), has demonstrated histology-agnostic efficacy in patients with TRK fusion–positive cancers.
Barry S. Taylor, Paul D. Larsen, Dorothea N. Douglas-Lindsay, Andrew Parker, Steve Andrews, Wen-I Wu, Kevin Ebata, Bethany Hanusch, Alexander Drilon, Shannon L. Winski, Paul R. Gordon, Ryma Benayed, Brian B. Tuch, David M. Hyman, Robyn Hamor, Nora Ku, Alison M. Schram, Steve Smith, Veronique Lauriault, Francis X. Sullivan, S. Michael Rothenberg, James F. Blake, Barbara J. Brandhuber, Lance A. Wollenberg, Ramamoorthy Nagasubramanian, Gabrielle R. Kolakowski, Maurizio Scaltriti, Tony H. Morales, Sandeep Raj, Philip Jonsson, Michael F. Berger, Karyn S. Bouhana, Walter E. DeWolf, Jaclyn F. Hechtman   +33 more
core   +1 more source

Boosting pancreatic cancer chemotherapy by disrupting nerve–cancer crosstalk

Acta Materia Medica
A preclinical study has developed a precision nano-intervention strategy targeting tumor-associated nerves to destroy nerve-fueled tumor growth in pancreatic cancer.
Yutian Xia, Jianzhong Zhang
doaj   +1 more source

Crosstalk Between Cortical Plasticity and Peripheral Nervous Injury: Insights, Mechanisms, and Future Directions

CNS Neuroscience &Therapeutics, Volume 32, Issue 9, September 2026.
Peripheral nerve injury induces dynamic cortical plasticity, driven by molecular mechanisms such as BDNF and neurotransmitter systems. This review synthesizes subtype‐specific plasticity patterns: compressive injuries trigger rapid reorganization, while metabolic neuropathies lead to maladaptive changes.
Cong Cheng, Dong Gao, Yaojie Shen, Xi Wang, Junxi Dai, Yaoxian Xiang, Zongyuan Jiang, Zongqi You, Junjian Jiang   +8 more
wiley   +1 more source

Neurotrophin receptors (Trk A, Trk B, and Trk C) in the developing and adult human retina

, 1999
In this study, the ontogeny and distribution patterns of three neurotrophin receptors (Trk A, Trk B, and Trk C) were examined in the human retinas. Immunohistochemistry was performed on sections of retina and optic nerve from fetuses (11-24 weeks of ...
Tapas C Nag, Shashi Wadhwa, Nag, Tapas C., Wadhwa, Shashi   +3 more
core   +1 more source

Prevalence, treatment response, and survival in a real-world NTRK gene fusion-positive microsatellite instability-high metastatic colorectal cancer cohort

ESMO Real World Data and Digital Oncology
Background: Tropomyosin receptor kinase (TRK) inhibitors are approved for patients with neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumors, but clinical benefit in metastatic colorectal cancer (mCRC) is uncertain.
S.J. Schraa, M.M. Laclé, K. Zwart, E.H. Gort, W.W. de Leng, M. Koopman, G.R. Vink, G.M. Bol   +7 more
doaj   +1 more source

From Executor to Orchestrator: The Pharmacology Scientist in the Age of Agentic AI

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 648-662, September 2026.
Drug development productivity has not improved despite five decades of computational advancement, with the probability that a compound entering Phase I achieving regulatory approval remaining near 10%. Each automation wave increased throughput while leaving the interpretive bottleneck intact; scientists continued to formulate questions, evaluate ...
Michael McCoy, Matthew McCoy
wiley   +1 more source

TRK Inhibition:A New Tumor-Agnostic Treatment Strategy [PDF]

, 2018
Oncogenic somatic chromosomal rearrangements involving the NTRK1, NTRK2 or NTRK3 genes (NTRK gene fusions) occur in up to 1% of all solid tumors, and have been reported across a wide range of tumor types.
Lassen, Ulrik N, Kummar, Shivaani
core   +1 more source